Delivering innovation with integrity: Raising the bar for childhood cancer care in LMICs

Access Cancer Treatment (ACT) for Children is a multi-stakeholder initiative designed to address one of the most urgent challenges in global pediatric oncology: ensuring that children in low- and middle-income countries (LMICs) receive high-quality, innovative cancer medicines.

In too many settings, children face treatment failure, increased toxicity, and avoidable death—not because cancer is untreatable, but because the medicines available are of poor quality, unregulated, outdated, or even counterfeit.

Delays in introducing innovative therapies come at a cost: older chemotherapies are often more toxic, less effective, and associated with long-term side effects that impact survivors for life. Timely access to modern, targeted treatments is not a luxury—it is a medical and ethical imperative.

To respond to this crisis, ACT for Children brings together industry, the medical community, and patient advocates to safely introduce and monitor quality-assured, innovative therapies in LMICs.

The program is built on a hospital-centered model supported by three pillars:

1. Access to quality-assured, innovative medicines

2. Expert medical management

3. Patient-centered supportive care

To ensure safety and sustainability, data is collected through retrospective and prospective registries and a Quality Improvement Study (QIS) that guides clinical use and informs national policy and investment.

ACT for Children offers a scalable model for the safe, equitable, and effective introduction of childhood cancer medicines—bridging the fatal gap too often left by unregulated markets, outdated treatment standards, and fragmented access pathways.

Breakfast will be served outside of the room starting at 7:30.

Session will start at 7:45 until 8:45.

Limited capacity